All around the world, the Ottobock name stands for high-quality, technologically outstanding products and services in the field of medical technology. The goal of helping to restore mobility for people with disabilities – and protect the mobility they have retained – stands behind each and every one of the company’s products. Our conviction that quality of life is closely connected to a maximum of individual freedom and independence is a key concept that has been a major influence throughout the company’s 100-year history. It also provides targeted focus for the development of new products. The family business that has been operating in the legal form SE & Co. KGaA since 2018 is 80 percent owned by Näder Holding GmbH & Co. KG, which wholly belongs to the Näder family. Swedish private equity firm EQT holds a 20 per cent share in Ottobock SE & Co. KGaA.

With regard to the company figures, Ottobock has been on a stable growth course for years: 2018 sales increased by 6.7 percent** to 927 million euros compared to the previous year. The company employs more than 7,000 people worldwide. The company’s international activities are coordinated from the head office in Duderstadt. A network consisting of sales and service companies in 58 countries gives the company a global presence which enables close proximity to its customers. Thanks to the Prosthetics, Orthotics, Human Mobility (manual and power wheelchairs, rehabilitation products) and Ottobock Industrials business segments as well as the Clinical Services Network, the company is perfectly positioned and capable of offering its customers a nearly incomparable breadth of products, perfectly harmonised solutions and extensive services.

In cooperation with the PFH Private University of Applied Sciences in Göttingen and the University of Göttingen, as well as other partners in medicine and science, Ottobock has developed courses of study in the fields of orthobionics and healthcare technology. These courses bridge the gap between medical research, modern medicine and orthopaedic technology.

**On the basis of organic, currency-adjusted growth compared to previous year